InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Secret_Agent_Man who started this subject	4/24/2002 4:49:30 PM
From: quidditch	of 508

investor.intermune.com snip BRISBANE, Calif., Apr 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- InterMune, Inc. (Nasdaq: ITMN) announced today financial results from operations for the first quarter ended March 31, 2002. Total product sales were $18.8 million for the first quarter of 2002 compared to $5.5 million for the same quarter in 2001, an increase of 238%. Sales of Actimmune(R) (interferon gamma-1b) for the first quarter of 2002 were $17.7 million, compared to $4.9 million in the same period in 2001, an increase of 259%. quid

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next